OK got it, I would have thought that Eylea biosimilars are not bad news for OPT or its commercialization. However, with the share price down, I thought there might be a negative impact, and I was concerned that I failed to draw a line between the dots in your posting.
Anyway, in many respects, a successful Phase 3 trial, even with lower than expected sales, is still going to be a huge win for holders at 62 cents.
It was my understanding that there is nothing in Phase 3 pipeline that would be a competitor to Sozinibercept.
Ann: Opthea to Host Key Opinion Leader Event on April 3, 2024, page-55
-
- There are more pages in this discussion • 7 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add OPT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
59.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $735.5M | |||
| Open | High | Low | Value | Volume |
| 59.0¢ | 60.3¢ | 58.5¢ | $370.2K | 620.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 15 | 67051 | 59.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 59.5¢ | 29349 | 16 |
View Market Depth
| Last trade - 12.18pm 12/09/2024 (20 minute delay) ? |
| OPT (ASX) Chart |